Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly's Jardiance in a move expected to drive up the drug's sales.
Generic drugmaker Mylan NV , which has been under fire for price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it expected to cut less than 10 percent of its workforce in a restructuring to integrate acquisitions.
U.S regulators said on Friday they would allow Eli Lilly and Co to state that its diabetes drug Jardiance reduces risk of death from heart problems, lifting company shares almost 3 percent and potentially giving a strong boost to the drug's future sales.
NEW YORK Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.
The top executives at two of the largest U.S. drugmakers weighed in on Thursday for the first time on possible changes for the industry next year under U.S. President-elect Donald Trump.
Dec 1 U.S. President-elect Donald Trump could be more critical of drugmakers and their price increases than the industry expects, Allergan Inc Chief Executive Brent Saunders said on Thursday.
Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.
Nov 30 Most patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.
The failure of Eli Lilly and Co's Alzheimer's treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk. | Video
Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense.
- Gold: PRECIOUS-Gold heads to first weekly gain in 4 weeks after Fed rate hike
- Oil Report: Russia's Gazprom says gas exports up 8.3 pct y/y in Jan 1-Dec 15
- British Pound Report: UPDATE 2-Sterling drops as Brexit talks move to second round
- US Dollar Report: FOREX-Dollar index firmer as volumes thin ahead of holidays